悦康药业股价跌5.21%，广发基金旗下1只基金重仓，持有60.97万股浮亏损失90.84万元

Group 1 - The core point of the news is that Yuyuan Pharmaceutical experienced a decline of 5.21% in its stock price, reaching 27.10 yuan per share, with a total market capitalization of 12.195 billion yuan [1] - Yuyuan Pharmaceutical, established on August 14, 2001, and listed on December 24, 2020, focuses on the research and production of high-end chemical drugs, with significant revenue contributions from cardiovascular, digestive, diabetes, and anti-infection medications [1] - The main products contributing to the company's revenue include Ginkgo biloba extract injection, Tianma extract injection, Lansoprazole injection, Omeprazole enteric-coated capsules, Metformin sustained-release tablets, Cefuroxime sodium injection, and Ceftriaxone sodium injection, indicating strong future growth potential [1] Group 2 - According to data, Guangfa Fund holds a significant position in Yuyuan Pharmaceutical, with its Guangfa Balanced Return Mixed A Fund holding 609,700 shares, unchanged from the previous period, representing 2.19% of the fund's net value [2] - The Guangfa Balanced Return Mixed A Fund, established on June 23, 2021, has a current scale of 612 million yuan, with a year-to-date return of 3.48% and a one-year return of 17.78% [2]